Regeneron Pharmaceuticals, Inc., and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

Existing Users Log In
   
Forgot password? Click here to reset
New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field